- Home
- CNC vs DVAX Comparison
CNC vs DVAX Comparison
Compare CNC & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNC
- DVAX
- Stock Information
- Founded
- CNC 1984
- DVAX 1996
- Country
- CNC United States
- DVAX United States
- Employees
- CNC N/A
- DVAX N/A
- Industry
- CNC Medical Specialities
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- CNC Health Care
- DVAX Health Care
- Exchange
- CNC Nasdaq
- DVAX Nasdaq
- Market Cap
- CNC 14.3B
- DVAX 1.2B
- IPO Year
- CNC 2001
- DVAX 2004
- Fundamental
- Price
- CNC $35.98
- DVAX $10.11
- Analyst Decision
- CNC Hold
- DVAX Buy
- Analyst Count
- CNC 17
- DVAX 4
- Target Price
- CNC $39.88
- DVAX $26.50
- AVG Volume (30 Days)
- CNC 10.5M
- DVAX 1.2M
- Earning Date
- CNC 10-29-2025
- DVAX 11-05-2025
- Dividend Yield
- CNC N/A
- DVAX N/A
- EPS Growth
- CNC N/A
- DVAX N/A
- EPS
- CNC N/A
- DVAX N/A
- Revenue
- CNC $167,680,000,000.00
- DVAX $316,268,000.00
- Revenue This Year
- CNC $31.16
- DVAX $23.23
- Revenue Next Year
- CNC $0.94
- DVAX $16.57
- P/E Ratio
- CNC N/A
- DVAX N/A
- Revenue Growth
- CNC 14.57
- DVAX 26.66
- 52 Week Low
- CNC $25.08
- DVAX $9.20
- 52 Week High
- CNC $66.81
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- CNC 53.95
- DVAX 47.19
- Support Level
- CNC $33.76
- DVAX $10.11
- Resistance Level
- CNC $37.57
- DVAX $10.58
- Average True Range (ATR)
- CNC 1.44
- DVAX 0.24
- MACD
- CNC -0.15
- DVAX 0.00
- Stochastic Oscillator
- CNC 66.10
- DVAX 41.48
About CNC Centene Corporation
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.